Clinical Trial Update: GO-203-2C + Bortezomib For Relapsed Or Refractory MM [Phase 1]

View source ↗

Summary

A Phase 1 trial of GO-203-2C plus bortezomib for relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• GO-203-2C (GO-203-2C)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Status: WITHDRAWN